Published in AIDS Weekly, October 28th, 1996
In preclinical testing, PMPA has demonstrated potent activity against simian immunodeficiency virus (SIV) infection, a primate model for HIV. The Phase I/II randomized, double-blind, placebo-controlled human study is planned to assess the safety, tolerance, pharmacokinetics and anti-HIV activity of PMPA when administered by intravenous infusion to HIV infected patients.
The study was designed to enroll a total of 40 patients with CD4 cell counts greater than 200 cells/mm3 at the Johns Hopkins University School of Medicine,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.